Navigation Links
MD Buyline's User Satisfaction Report Awards MGC Diagnostics Pulmonary Function Products Top Rating for Fourth Consecutive Quarter
Date:3/4/2013

SAINT PAUL, Minn., March 4, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology company, today announced that its pulmonary function products, service and support continues to outperform industry competitors as well as increasing its margin above Market Average. As published in MD Buyline's User Satisfaction Report, MGC Diagnostics has earned the top rating in all categories for its fourth consecutive quarter. Ratings based on user satisfaction ranks MGC Diagnostics system performance, system reliability, installation/implementation, applications training, service response time and service repair quality singularly higher compared to other vendors in this space.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

Gregg O. Lehman , Ph.D., Chief Executive Officer and President of MGC Diagnostics, commented, "We are pleased to be recognized by our customers in the report from MD Buyline for consistently providing unmatched service and support, relentlessly making improvements and anticipating and solving unmet needs. These core commitments guide our strategy and define our commitment to customers, employees and shareholders making us uniquely qualified to solve today's challenges and uncover solutions for tomorrow's opportunities."

About MD Buyline – MD Buyline, the leading provider of healthcare technology and clinical research for reducing the purchasing costs across the healthcare supply chain, provides over 3,000 healthcare providers with unbiased, up-to-the-minute data on vendors, products, services, and user satisfaction ratings to ensure they invest in the right technology and services at the right price. www.mdbuyline.com

About MGC DiagnosticsMGC Diagnostics Corporation, (formerly Angeion Corporation) through its subsidiary Medical Graphics Corporation, is a global medical technology company dedicated to cardiorespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking StatementsFrom time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward−looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward−looking statements, the Company claims the protection of the safe harbor for forward−looking statements contained in federal securities laws. These forward−looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward−looking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.Contact:Gregg O. Lehman, Ph.D.Joe Dorame, Robert Blum, Joe DiazMGC Diagnostics CorporationLytham Partners, LLCChief Executive Officer(602) 889-9700(651) 484-4874mgcd@lythampartners.com 


'/>"/>
SOURCE MGC Diagnostics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prostate Cancer Study: Most Patients Report Satisfaction After Robotic Surgery
2. Single-Port Kidney Removal Through The Belly Button Boosts Living-Donor Satisfaction
3. Key-Whitman Eye Center Selects Versus RTLS for Patient Flow and Satisfaction
4. Diplomat Specialty Pharmacys 2012 Physician Satisfaction Survey Results Affirm Success of Companys Education & Training Program
5. Kaiser Permanente Ranks Highest in 2012 J.D. Power and Associates Employer Satisfaction Study for Second Year in a Row
6. New Medical Supplies Website to Increase Customer Accessibility and Satisfaction Through E-Commerce
7. China Nepstar Chain Drugstore to Report Fourth Quarter and Fiscal Year 2012 Financial Results on March 28, 2013
8. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
9. ECRI Institute PSO Offers Key Reports on Health IT and Medication Safety for Patient Safety Awareness Week
10. Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results
11. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
Breaking Medicine News(10 mins):